Johnson & Johnson surpasses expectations with strong Q1 performance and raised outlook.
TL;DR
Johnson & Johnson's Q1 revenue rose 5.6%, driven by demand for its consumer-health business, pharmaceutical products, and contact lenses. The company raised its full-year sales and earnings outlook. However, Q1 earnings were impacted by a $6.9 billion charge related to resolving talc lawsuits. Johnson & Johnson is spinning off its consumer-health business into a separate company.
Topics:business#business#consumer-health-business#johnson-and-johnson#pharmaceutical-products#q1-earnings#talc-lawsuits
- Johnson & Johnson Posts Higher Quarterly Sales, Raises 2023 Outlook The Wall Street Journal
- Johnson & Johnson beats on earnings and revenue, raises full-year guidance CNBC
- Johnson & Johnson stock declines despite Q1 earnings beat Yahoo Finance
- Johnson & Johnson Q1 Beats Street View On Strong Performance Across All Segments, Lifts Guidance, Dividends Yahoo Finance
- JNJ Stock: The Surprising Source Of Johnson & Johnson's First-Quarter Beat | Investor's Business Daily Investor's Business Daily
Want the full story? Read the original reporting
Read on The Wall Street Journal